Yu Honglu, Xiong Min, Zhang Zhentao
Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, China.
TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
Front Mol Neurosci. 2023 Sep 15;16:1209703. doi: 10.3389/fnmol.2023.1209703. eCollection 2023.
Neurodegenerative diseases (NDDs) pose an increasingly prevalent threat to the well-being and survival of elderly individuals worldwide. NDDs include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), and so on. They are characterized by progressive loss or dysfunction of neurons in the central or peripheral nervous system and share several cellular and molecular mechanisms, including protein aggregation, mitochondrial dysfunction, gene mutations, and chronic neuroinflammation. Glycogen synthase kinase-3 beta (GSK-3β) is a serine/threonine kinase that is believed to play a pivotal role in the pathogenesis of NDDs. Here we summarize the structure and physiological functions of GSK3β and explore its involvement in NDDs. We also discussed its potential as a therapeutic target.
神经退行性疾病(NDDs)对全球老年人的健康和生存构成了日益普遍的威胁。NDDs包括阿尔茨海默病(AD)、帕金森病(PD)、亨廷顿病(HD)、肌萎缩侧索硬化症(ALS)等。它们的特征是中枢或周围神经系统中神经元的渐进性丧失或功能障碍,并具有多种细胞和分子机制,包括蛋白质聚集、线粒体功能障碍、基因突变和慢性神经炎症。糖原合酶激酶-3β(GSK-3β)是一种丝氨酸/苏氨酸激酶,被认为在NDDs的发病机制中起关键作用。在此,我们总结了GSK3β的结构和生理功能,并探讨了其与NDDs的关系。我们还讨论了其作为治疗靶点的潜力。